格列美脲联合达格列净治疗2型糖尿病肾病的疗效及对BUN、CREA、ACR水平的影响

Efficacy of glimepiride combined with Dagliagrazin in the treatment of type 2 diabetic nephropathy and its effect on BUN,CREA and ACR levels

目的 探究格列美脲联合达格列净治疗2型糖尿病肾病的疗效及对尿素氮(BUN)、肌酐(CREA)、尿白蛋白/肌酐比值(ACR)水平的影响。方法 选取2021年3月至2023年3月120例临泉县人民医院内分泌科收治的2型糖尿病肾病患者为研究对象,依据治疗方式的不同分为达格列净治疗组(对照组)64例(给予达格列净治疗)与格列美脲联合达格列净治疗组(研究组)56例(给予格列美脲联合达格列净治疗)。对比两组临床疗效、血糖达标时间及胰岛素日用量间的差异,比较达格列净治疗组与格列美脲联合达格列净治疗组治疗前后的血糖指标及BUN、CREA、ACR水平。结果 格列美脲联合达格列净治疗组临床治疗总有效率96.43%显著高于达格列净治疗组82.81%,差异具有统计学意义(χ^(2)=2.006,P<0.05)。治疗12周后,与达格列净治疗组比较,格列美脲联合达格列净治疗组血糖达标时间明显缩短,胰岛素日用量也显著减少,差异均有统计学意义(t=4.449、9.958,P<0.05)。两组FPG、HbA1 c、BUN、CREA、ACR水平均下降,且格列美脲联合达格列净治疗组FPG、HbA1 c、BUN、CREA、ACR水平低于达格列净治疗组,差异有统计学意义(t=4.382、4.028、20.741、2.930、2.360,P<0.05)。结论 与单用达格列净治疗相比,采用格列美脲联合达格列净治疗可有效改善2型糖尿病肾病患者血糖控制情况,调节胰岛素抵抗状态,降低BUN、CREA、ACR水平。

Objective To explore the efficacy of glimepiride combined with dagliprazin in the treatment of type 2 diabetic nephropathy and the effects on the levels of urea nitrogen(BUN),creatinine(CREA)and urinary albumin/creatinine ratio(ACR).Methods 120 patients with type 2 diabetic nephropa-thy who were admitted to the Endocrinology Department of Linquan County People’s Hospital from March 2021 to Manch 2023 were selected as the study subjects.They were divided into two groups based on different treatment methods:64 cases received dagliaglizin treatment,while 56 cases received glimepiride combined with dagliprazin treatment.The treatment duration was 12 weeks.The differences in clinical efficacy,blood glucose standard time and daily insulin dosage between the two groups were compared,and the blood glucose indexes,BUN,CREA and ACR levels before and after treatment were compared between the dagliaglizin treatment group and the glimepiride combined with dagliprazin treatment group.Results The total effective rate of glimepiride combined with dagliprazin group was 96.43%,which was significantly higher than that of dagliprazin group(82.81%),the difference was statistically significant(χ^(2)=2.006,P<0.05).After 12 weeks of treatment,compared with dagliagrazin treatment group,the blood glucose standard time of glimepiplus combined with dagliagin treatment group was significantly shortened,and the daily insulin dosage was also sig-nificantly reduced,with statistical significance(t=4.449,9.958,P<0.05).The levels of FPG,HbA1c,BUN,CREA,and ACR in both groups were decreased,and the levels of FPG,HbA1c,BUN,CREA,and ACR in glimepiplus combined with dagliagin group were lower than those in Dagliagin group,with statistical significance(t=4.382,4.028,20.741,2.930,2.360,P<0.05).Conclusion Compared to using daaglizin alone,the combination of glimepiride and dagliprazin can effectively enhance blood glucose control,regulate insulin resistance,and reduce BUN,CREA and ACR levels in patients with type 2 diabetic nephropathy.